[
    [
        {
            "time": "2020-07",
            "original_text": "2020年7月份上海证券研究所投资组合报告",
            "features": {
                "keywords": [
                    "上海证券",
                    "投资组合",
                    "报告"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2020年7月份上海证券研究所投资组合报告",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 4,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-07",
            "original_text": "【民生医药|行业周报】板块普涨，关注成长性更强的CXO和API板块",
            "features": {
                "keywords": [
                    "民生医药",
                    "行业周报",
                    "板块普涨",
                    "CXO",
                    "API"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO",
                    "API"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|行业周报】板块普涨，关注成长性更强的CXO和API板块",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-07",
            "original_text": "【民生医药】医药外包行业专题：从人效角度看中国医药外包公司的商业模式拓展",
            "features": {
                "keywords": [
                    "民生医药",
                    "医药外包",
                    "商业模式",
                    "人效"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "外包行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【民生医药】医药外包行业专题：从人效角度看中国医药外包公司的商业模式拓展",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]